Compare · LLY vs NHWK
LLY vs NHWK
Side-by-side comparison of Eli Lilly and Company (LLY) and NightHawk Biosciences Inc. (NHWK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and NHWK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY carries a market cap of $1.06T.
- LLY has hit the wire 13 times in the past 4 weeks while NHWK has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 0 for NHWK).
- Company
- Eli Lilly and Company
- NightHawk Biosciences Inc.
- Price
- $1121.18-2.41%
- $0.42+16.34%
- Market cap
- $1.06T
- -
- 1M return
- -7.40%
- -
- 1Y return
- +45.82%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2022
- News (4w)
- 13
- 0
- Recent ratings
- 25
- 0
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- EVP, Global Quality Seymour Melissa converted options into 981 shares and covered exercise/tax liability with 439 shares, increasing direct ownership by 103% to 1,067 units (SEC Form 4)
- Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
- New insider Eli Lilly & Co claimed ownership of 1,054,828 shares (SEC Form 3)
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
- Lilly confirms date and conference call for second-quarter 2026 financial results announcement
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,000 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,905 units (SEC Form 4)
- Director Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,410 units (SEC Form 4)
- Director Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,734 units (SEC Form 4)
- Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
Latest NHWK
- Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University
- Scorpius Holdings Accepted as a Member of the US Government's BioMaP-Consortium
- Scorpius Holdings, Inc. Announces Closing of Public Offering
- Scorpius Holdings, Inc. Announces Pricing of Public Offering
- Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock
- Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023
- NightHawk Biosciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- NightHawk Biosciences Completes Name Change To Scorpius Holdings; Trading To Commence Under "SCPX" Effective At The Market Open Today
- NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under "SCPX" Effective at the Market Open Today
- NightHawk's Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer